NewAmsterdam Pharma (NAMS) Research & Development (2023 - 2026)
NewAmsterdam Pharma's Research & Development was $41.67 million in Q2 2026, up 51.5% from $27.52 million a year earlier and up 9.6% from the prior quarter.
Powered by 
Analysis
NewAmsterdam Pharma (NAMS) Research & Development (2023 - 2026) Analysis & Trends
On a trailing twelve-month basis, NewAmsterdam Pharma's Research & Development was $149.25 million through Jun 30, 2026, up 4.5% year-over-year; for FY2025, it was $141.83 million, down 6.3% from FY2024.
- Research & Development shows a five-year compound annual growth rate of 98.4% (FY2020 to FY2025).
- In earlier years, Research & Development was $151.41 million in FY2024 (-5.0%), $159.42 million in FY2023 (+83.8%), $86.74 million in FY2022 (+199.4%) and $28.97 million in FY2021 (+527.3%).
- The Q2 2026 figure marks the highest quarterly Research & Development since Q1 2025.
- Compared with a year earlier, Research & Development was higher in three of the last eight quarters, with an average decline of 2.8%.
- The best year-over-year quarter for Research & Development over five years was Q2 2026 (growth of 51.5%); the worst was Q2 2025 (a decline of 28.3%).
- Per Business Quant data, NAMS's Research & Development in the three quarters before Q2 2026 was $38.01 million (Q1 2026), $38.59 million (Q4 2025) and $30.97 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,264.65 Bn | 1,238.27 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 677.74 Bn | 597.60 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 517.10 Bn | 485.11 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 362.23 Bn | 325.17 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 315.90 Bn | 276.16 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 289.40 Bn | 266.24 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 249.90 Bn | 201.56 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 209.15 Bn | 184.26 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 165.88 Bn | 113.23 Bn | 12.56 Bn | 3.02 Bn |
| 10 | NewAmsterdam Pharma | 2.43 Bn | -108.81 Mn | - | 39.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 39.36 Mn |
| Jun 30, 2026 | 41.67 Mn |
| Mar 31, 2026 | 38.01 Mn |
| Dec 31, 2025 | 38.59 Mn |
| Sep 30, 2025 | 30.97 Mn |
| Jun 30, 2025 | 27.52 Mn |
| Mar 31, 2025 | 44.75 Mn |
| Dec 31, 2024 | 34.90 Mn |
| Sep 30, 2024 | 35.70 Mn |
| Jun 30, 2024 | 38.38 Mn |
| Mar 31, 2024 | 42.43 Mn |
| Dec 31, 2023 | 41.29 Mn |
| Sep 30, 2023 | 43.37 Mn |
| Jun 30, 2023 | 34.34 Mn |
| Mar 31, 2023 | 40.42 Mn |
API Access
NewAmsterdam Pharma Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=NAMS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "NAMS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=NAMS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();